Compare BLDR & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLDR | GKOS |
|---|---|---|
| Founded | 1998 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | RETAIL: Building Materials | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0B | 9.0B |
| IPO Year | 2005 | 2015 |
| Metric | BLDR | GKOS |
|---|---|---|
| Price | $67.14 | $170.51 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 12 |
| Target Price | $121.76 | ★ $126.92 |
| AVG Volume (30 Days) | ★ 2.1M | 747.7K |
| Earning Date | 04-30-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $15,190,638,000.00 | $507,442,000.00 |
| Revenue This Year | $0.71 | $23.32 |
| Revenue Next Year | $4.52 | $27.43 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 32.33 |
| 52 Week Low | $65.10 | $73.16 |
| 52 Week High | $151.03 | $166.00 |
| Indicator | BLDR | GKOS |
|---|---|---|
| Relative Strength Index (RSI) | 36.61 | 69.55 |
| Support Level | $65.10 | $98.22 |
| Resistance Level | $79.90 | N/A |
| Average True Range (ATR) | 3.41 | 7.15 |
| MACD | -0.54 | -0.60 |
| Stochastic Oscillator | 2.78 | 81.04 |
Builders FirstSource Inc is a manufacturer and supplier of building materials. The company offers structural and related building products such as factory-built roof and floor trusses, wall panels and stairs, vinyl windows, custom millwork and trim, and engineered wood. The products can be designed for each home individually and are installed by Builders FirstSource. The company's construction-related services include professional installation, turn-key framing, and shell construction. Builders FirstSource's customers range from large production builders to small custom homebuilders.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.